Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

-Ahead of print
-Authors' Accepted
    Manuscripts
new!
-Current Issue
-Archive
-Acknowledgments
-Special Issues
-Browse by Category

Manuscript Submission

-Online Submission
-Online Review
-Instruction for Authors
-Instruction for Reviewers
-English Corner new!

About AJA

-About AJA
-Editorial Board
-Contact Us
-News

Resources & Services

-Advertisement
-Subscription
-Email alert
-Proceedings
-Reprints

Download area

-Copyright licence
-EndNote style file
-Manuscript word template
-Guidance for AJA figures
    preparation (in English)

-Guidance for AJA figures
    preparation (in Chinese)

-Proof-reading for the
    authors

-AJA Club (in English)
-AJA Club (in Chinese)

 
Abstract

Volume 27, Issue 3 (May 2025) 27, 330–341; 10.4103/aja2024104

Clinician’s guide to the management of azoospermia induced by exogenous testosterone or anabolic–androgenic steroids

Al Hashimi, Manaf1,2,*; Pinggera, Germar-Michael1,3,*; Shah, Rupin1,4; Agarwal, Ashok1,5

1Global Andrology Forum, 130 West Juniper Lane, Moreland Hills, OH 44022, USA

2Department of Urology, Burjeel Hospital-Abu Dhabi, Abu Dhabi, United Arab Emirates

3Department of Urology, Innsbruck Medical University, Innsbruck 6020, Austria

4Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, Maharashtra 400050, India

5Cleveland Clinic, Cleveland, OH 44195, USA

Correspondence: Dr. GM Pinggera (urologie.pinggera@gmail.com)

Originally published: January 17, 2025 Received: December 27, 2023 Accepted: October 16, 2024

Abstract

Azoospermia, defined as the absence of sperm in the ejaculate, is a well-documented consequence of exogenous testosterone (ET) and anabolic–androgenic steroid (AAS) use. These agents suppress the hypothalamic–pituitary–gonadal (HPG) axis, leading to reduced intratesticular testosterone levels and impaired spermatogenesis. This review examines the pathophysiological mechanisms underlying azoospermia and outlines therapeutic strategies for recovery. Azoospermia is categorized into pretesticular, testicular, and post-testicular types, with a focus on personalized treatment approaches based on the degree of HPG axis suppression and baseline testicular function. Key strategies include discontinuing ET and monitoring for spontaneous recovery, particularly in patients with shorter durations of ET use. For cases of persistent azoospermia, gonadotropins (human chorionic gonadotropin [hCG] and follicle-stimulating hormone [FSH]) and selective estrogen receptor modulators (SERMs), such as clomiphene citrate, are recommended, either alone or in combination. The global increase in exogenous testosterone use, including testosterone replacement therapy and AAS, underscores the need for improved management of associated azoospermia, which can be temporary or permanent depending on individual factors and the type of testosterone used. Additionally, the manuscript discusses preventive strategies, such as transitioning to short-acting testosterone formulations or incorporating low-dose hCG to preserve fertility during ET therapy. While guidelines for managing testosterone-related azoospermia remain limited, emerging research indicates the potential efficacy of hormonal stimulation therapies. However, there is a notable lack of well-structured, controlled, and long-term studies addressing the management of azoospermia related to exogenous testosterone use, highlighting the need for such studies to inform evidence-based recommendations.

Keywords: anabolic–androgenic steroids; azoospermia; male infertility; recommendations; testosterone

Full Text | PDF |

 
Browse:  2183
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.